1
|
Song YY, Zhou YZ, Wang YF, Shu TY, Feng Y, Xu M, Su LH, Li HZ. Sesquiterpenoids from aged Artemisia argyi and their 3D-QSAR for anti-HBV activity. PHYTOCHEMISTRY 2024; 217:113912. [PMID: 37918620 DOI: 10.1016/j.phytochem.2023.113912] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/17/2023] [Revised: 10/30/2023] [Accepted: 10/31/2023] [Indexed: 11/04/2023]
Abstract
Artemisia argyi Levl. Et Vant, commonly known as "Chinese Mugwort," has been utilized in traditional Chinese medicine and cuisine for centuries. Aged Chinese Mugwort has been uncovered to possess superior quality and safety, and its ethyl acetate extract has been found to exhibit anti-hepatitis B virus (HBV) activity. In this study, twenty-five sesquiterpenoids were isolated and characterized from three-year-aged A. argyi. Among them, 14 previously undescribed sesquiterpenoids (1-14), featuring double bond oxidation or ring opening. It is hypothesized that during the aging process, sesquiterpenes undergo oxidative transformation of their double bonds to form alcohols due to external factors and inherent properties. The anti-HBV activity and cytotoxicity of all compounds were assessed in vitro using HepG 2.2.15 cells, and their structure-activity relationships were analyzed through three-dimensional quantitative structure-activity relationship (3D-QASR) techniques. The α-methylene-γ-lactone sesquiterpenoid derivatives were discovered to have potent inhibitory activity against HBV. This research may broaden the potential applications of Chinese Mugwort and offer further guidance for its development and utilization as functional food or traditional Chinese medicine.
Collapse
Affiliation(s)
- Yu-Ying Song
- Laboratory of Medicinal Chemical Biology, Facaulty of Life Science and Technology, Kunming University of Science and Technology, Kunming, 650500, China.
| | - Yong-Zhi Zhou
- Laboratory of Medicinal Chemical Biology, Facaulty of Life Science and Technology, Kunming University of Science and Technology, Kunming, 650500, China.
| | - Yun-Fen Wang
- Laboratory of Medicinal Chemical Biology, Facaulty of Life Science and Technology, Kunming University of Science and Technology, Kunming, 650500, China.
| | - Teng-Yun Shu
- Laboratory of Medicinal Chemical Biology, Facaulty of Life Science and Technology, Kunming University of Science and Technology, Kunming, 650500, China.
| | - Yang Feng
- Laboratory of Medicinal Chemical Biology, Facaulty of Life Science and Technology, Kunming University of Science and Technology, Kunming, 650500, China.
| | - Min Xu
- Laboratory of Medicinal Chemical Biology, Facaulty of Life Science and Technology, Kunming University of Science and Technology, Kunming, 650500, China.
| | - Li-Hua Su
- Laboratory of Medicinal Chemical Biology, Facaulty of Life Science and Technology, Kunming University of Science and Technology, Kunming, 650500, China.
| | - Hai-Zhou Li
- Laboratory of Medicinal Chemical Biology, Facaulty of Life Science and Technology, Kunming University of Science and Technology, Kunming, 650500, China.
| |
Collapse
|
2
|
Liang X, Xie Q, Shang J, Tang H, Xu M, Meng Q, Zhang J, Gao P, Sheng J, Wang H, Jia J, Wang G, Wu S, Ping J, Hou J. Tenofovir disoproxil fumarate for multiple nucleos(t)ide analogues treatment failure hepatitis B: Is monotherapy enough? J Gastroenterol Hepatol 2022; 37:471-479. [PMID: 34894002 PMCID: PMC9303406 DOI: 10.1111/jgh.15757] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/27/2021] [Revised: 11/10/2021] [Accepted: 12/01/2021] [Indexed: 02/05/2023]
Abstract
BACKGROUND AND AIM Tenofovir disoproxil fumarate (TDF) is a first-line treatment for chronic hepatitis B virus (HBV) infection for its high potency and a low rate of drug resistance. This study investigated the efficacy and safety of TDF in Chinese patients with chronic hepatitis B (CHB) infection after treatment failure with multiple nucleos(t)ide analogues (NAs). METHODS Patients included were aged 18-65 years, with treatment failure with multiple NAs (serum HBV DNA > 200 IU/mL after more than two different NA treatments). The primary endpoint was proportion of patients with serum HBV DNA < 20 IU/mL at Week 144 of TDF monotherapy. Secondary endpoints and safety were also assessed. RESULTS Overall, 213 patients were enrolled. At Week 144, mean HBV DNA decreased significantly from baseline (4.4 vs 1.4 log10 IU/mL), with 77.0% patients (95% confidence interval: 71.1, 82.9) achieving serum HBV DNA < 20 IU/mL. Three (1.4%) patients experienced virological breakthrough during TDF monotherapy, without hepatitis flare. At Week 144, 15.3% and 4.7% patients (hepatitis B e antigen [HBeAg]-positive at baseline) experienced HBeAg loss and HBeAg seroconversion, respectively; 68.3% patients achieved normalized alanine aminotransferase levels. Overall, 58.7% patients experienced more than one adverse event (AE). Most common AEs were upper respiratory tract infection and blood creatine phosphokinase increase; 8.5% patients experienced study drug-related AEs; 9.4% patients experienced serious AEs (none were TDF-related). Among renal safety parameters, overall trend of mean serum phosphorous level remained stable, while mean estimated glomerular filtration rate increased slightly. CONCLUSIONS Tenofovir disoproxil fumarate monotherapy is efficacious in CHB patients with multiple NAs treatment failure with no new safety findings.
Collapse
Affiliation(s)
- Xieer Liang
- Nanfang HospitalSouthern Medical UniversityGuangzhouChina
| | - Qing Xie
- School of MedicineRuijin Hospital Affiliated to Jiaotong UniversityShanghaiChina
| | - Jia Shang
- Department of Infectious DiseasesHenan Provincial People's HospitalZhengzhouChina
| | - Hong Tang
- West China Hospital of Sichuan UniversityChengduChina
| | - Min Xu
- Guangzhou Eighth Municipal People's HospitalGuangzhouChina
| | - Qinghua Meng
- Beijing You‐An HospitalCapital Medical UniversityBeijingChina
| | - Jiming Zhang
- Huashan Hospital Affiliated to Fudan UniversityShanghaiChina
| | - Pujun Gao
- The First Hospital of Jilin UniversityChangchunChina
| | - Jifang Sheng
- Department of Infectious Diseases, Collaborative Innovation Centre for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of MedicineZhejiang UniversityHangzhouChina
| | - Hao Wang
- Peking University People's HospitalBeijingChina
| | - Jidong Jia
- Beijing Friendship HospitalCapital Medical UniversityBeijingChina
| | | | - Shunquan Wu
- GlaxoSmithKline R&D Company LimitedShanghaiChina
| | - Jingna Ping
- GlaxoSmithKline R&D Company LimitedShanghaiChina
| | - Jinlin Hou
- Nanfang HospitalSouthern Medical UniversityGuangzhouChina
| |
Collapse
|
3
|
Shao J, Gong Q, Yin Z, Pan W, Pandiyan S, Wang L. S2DV: converting SMILES to a drug vector for predicting the activity of anti-HBV small molecules. Brief Bioinform 2022; 23:6513448. [PMID: 35062019 PMCID: PMC8921627 DOI: 10.1093/bib/bbab593] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2021] [Revised: 12/20/2021] [Accepted: 12/22/2021] [Indexed: 01/02/2023] Open
Abstract
In the past few decades, chronic hepatitis B caused by hepatitis B virus (HBV) has been one of the most serious diseases to human health. The development of innovative systems is essential for preventing the complex pathogenesis of hepatitis B and reducing side effects caused by drugs. HBV inhibitory drugs have been developed through various compounds, and they are often limited by routine experimental screening and delay drug development. More recently, virtual screening of compounds has gradually been used in drug research with strong computational capability and is further applied in anti-HBV drug screening, thus facilitating a reliable drug screening process. However, the lack of structural information in traditional compound analysis is an important hurdle for unsatisfactory efficiency in drug screening. Here, a natural language processing technique was adopted to analyze compound simplified molecular input line entry system strings. By using the targeted optimized word2vec model for pretraining, we can accurately represent the relationship between the compound and its substructure. The machine learning model based on training results can effectively predict the inhibitory effect of compounds on HBV and liver toxicity. The reliability of the model is verified by the results of wet-lab experiments. In addition, a tool has been published to predict potential compounds. Hence, this article provides a new perspective on the prediction of compound properties for anti-HBV drugs that can help improve hepatitis B diagnosis and further develop human health in the future.
Collapse
Affiliation(s)
| | - Qineng Gong
- Department of Medicinal Chemistry, School of Pharmacy, Fudan University
| | - Zeyu Yin
- School of Information Science and Technology, Nantong University, Nantong, China
| | - Wenjie Pan
- department of medical informatics, Nantong University
| | | | - Li Wang
- Corresponding author. Li Wang, School of Information Science and Technology, Research Center for Intelligence Information Technology, Nantong University, Nantong, Jiangsu 226019, China. Tel.: +86 159 5131 8963; Fax: +86 (0513) 55003030. E-mail:
| |
Collapse
|
4
|
Wang G, Duan Z. Guidelines for Prevention and Treatment of Chronic Hepatitis B. J Clin Transl Hepatol 2021; 9:769-791. [PMID: 34722192 PMCID: PMC8516840 DOI: 10.14218/jcth.2021.00209] [Citation(s) in RCA: 23] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/05/2021] [Revised: 07/20/2021] [Accepted: 08/03/2021] [Indexed: 12/12/2022] Open
Abstract
To achieve the goal of the World Health Organization to eliminate viral hepatitis as a major public health threat by 2030, the Chinese Society of Infectious Diseases and the Chinese Society of Hepatology convened an expert panel in 2019 to update the guidelines for the prevention and treatment of chronic hepatitis B (CHB). The current guidelines cover recent advances in basic, clinical, and preventive studies of CHB infection and consider the actual situation in China. These guidelines are intended to provide support for the prevention, diagnosis, and treatment of CHB.
Collapse
Affiliation(s)
- Guiqiang Wang
- Center for Liver Diseases, Department of Infectious Diseases, Peking University First Hospital; Department of Infectious and Liver Diseases, Peking University International Hospital, Beijing, China
- Correspondence to: Guiqiang Wang, Center for Liver Diseases, Department of Infectious Diseases, Peking University First Hospital; Department of Infectious and Liver Diseases, Peking University International Hospital, Beijing 100034, China. ORCID: https://orcid.org/0000-0003-0515-6806. Tel: +86-10-8357-2840, Fax: +86-10-6655-1680, E-mail: ; Zhongping Duan, Center for Difficult and Complicated Liver Diseases and Artificial Liver, Beijing YouAn Hospital, Capital Medical University, Beijing 100069, China. ORCID: https://orcid.org/0000-0002-9397-6330. Tel: +86-10-8399-7349, Fax: +86-10-6329-5285, E-mail:
| | - Zhongping Duan
- Center for Difficult and Complicated Liver Diseases and Artificial Liver, Beijing YouAn Hospital, Capital Medical University, Beijing, China
- Correspondence to: Guiqiang Wang, Center for Liver Diseases, Department of Infectious Diseases, Peking University First Hospital; Department of Infectious and Liver Diseases, Peking University International Hospital, Beijing 100034, China. ORCID: https://orcid.org/0000-0003-0515-6806. Tel: +86-10-8357-2840, Fax: +86-10-6655-1680, E-mail: ; Zhongping Duan, Center for Difficult and Complicated Liver Diseases and Artificial Liver, Beijing YouAn Hospital, Capital Medical University, Beijing 100069, China. ORCID: https://orcid.org/0000-0002-9397-6330. Tel: +86-10-8399-7349, Fax: +86-10-6329-5285, E-mail:
| |
Collapse
|
5
|
Zheng S, Liu L, Lu J, Zhang X, Shen H, Zhang H, Xue Y, Lin L. Efficacy and safety of tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B virus infection: A 2-year prospective study. Medicine (Baltimore) 2019; 98:e17590. [PMID: 31626130 PMCID: PMC6824756 DOI: 10.1097/md.0000000000017590] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
To date, a small number of studies concerning the effects and safety of tenofovir disoproxil fumarate (TDF) in Chinese individuals were conducted. In this study, we aimed to assess the antiviral effects and nephrotoxicity of TDF in Chinese patients with chronic hepatitis B virus (HBV) infection.Patients with chronic HBV infection were prospectively recruited and TDF treatment was given for 96 weeks. HBV serologic markers, HBV DNA, creatinine and phosphorus were collected.Fifty-seven treatment-naïve and 48 treatment-experienced patients were recruited. Irrespective of the prior treatment history, more than 95% of patients achieved virological response during 96 weeks treatment with TDF. Estimated glomerular filtration rate (eGFR) significantly declined in the first year of treatment in patients with chronic hepatitis B or younger age (<65 years old) (both P < .05), while that was not achieved in patients with liver cirrhosis or older age (≥65 years old) (both P > .05). For patients who were treatment-naïve or treated previously with adefovir dipivoxil, eGFR declined at the 48th week; however, eGFR was partially recovered at the 96th week. Furthermore, multivariable analysis showed that basal eGFR <90 mL/min/1.73 m (P = .001; odds ratio: 4.821; 95% confidence interval: 1.904-12.206) is the only independent risk factor for eGFR <90 mL/min/1.73 m at the 96th week.TDF has potent antiviral effect in both treatment-naïve and treatment-experienced patients.
Collapse
Affiliation(s)
- Shuqin Zheng
- Department of Liver Diseases
- Institute for the Study of Liver Diseases
| | - Longgen Liu
- Department of Liver Diseases
- Institute for the Study of Liver Diseases
| | - Jianchun Lu
- Department of Liver Diseases
- Institute for the Study of Liver Diseases
| | - Xiujun Zhang
- Department of Liver Diseases
- Institute for the Study of Liver Diseases
| | | | | | - Yuan Xue
- Department of Liver Diseases
- Institute for the Study of Liver Diseases
| | - Lin Lin
- Institute for the Study of Liver Diseases
- Department of Pharmacy, The Third People's Hospital of Changzhou, Changzhou, Jiangsu, China
| |
Collapse
|
6
|
Yang J, Chen J, Ji Y, Tang Q, Zhang R, Liu L, Shen Y, Xun J, Song W, Tang Y, Wang Z, Qi T, Lu H. Lipid profile and renal safety of tenofovir disoproxil fumarate-based anti-retroviral therapy in HIV-infected Chinese patients. Int J Infect Dis 2019; 83:64-71. [PMID: 30951879 DOI: 10.1016/j.ijid.2019.03.034] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2019] [Revised: 03/27/2019] [Accepted: 03/28/2019] [Indexed: 12/21/2022] Open
Abstract
BACKGROUND Tenofovir disoproxil fumarate (TDF) is an important component of antiretroviral therapy (ART) that has been widely used. The aim of this study was to observe the long-term impact of TDF-based ART on lipid metabolism profiles and renal functions in Chinese patients. METHODS 414 and 124 HIV-infected, ART-naïve patients who initiated TDF-based regimens and non-TDF regimens respectively were retrospectively included. Demographic characteristics and clinical information of each patient was collected. Changes of lipid profiles and renal function, as well as the risk factors of hyperlipidemia and renal dysfunction were analyzed. RESULTS After 96 weeks of ART, HIV viral loads were undetectable in 97.34% (403/414) of patients exposed to TDF. The plasma total cholesterol (TCH) increased from 3.97 ± 0.83 mmol/L to 4.53 ± 0.87 mmol/L (P < 0.001), which did not show a significant difference comparing with non-TDF exposed group. By contrast, the plasma triglyceride (TG) levels increased, but were still lower than that in the non-TDF exposed group (0.26 ± 1.24 vs. 0.89 ± 1.78, P < 0.001). The mean estimated glomerular filtration rate (eGFR) decreased from 127.29 ± 24.04ml∙min-1∙1.73 m-2 at baseline to 118.84 ± 22.74 ml∙min-1∙1.73 m-2(P < 0.001) in the TDF exposed group, while it increased in the non-TDF exposed group. In the TDF group, high body mass index (BMI) (OR = 1.13, P = 0.01), high baseline TG (OR = 2.33, P<0.001) and receiving protease inhibitors (PIs) (OR = 7.58, P < 0.001) were associated with hypertriglyceridemia after ART, while high baseline TCH predicted hypercholesterolemia (OR = 3.58, P < 0.001). MSM (OR = 0.22, P = 0.02) and baseline eGFR (OR = 0.90, P < 0.001) was associated with renal dysfunction after ART. CONCLUSIONS TDF-based regimens are of good therapeutic effect among Chinese people. These regimens showed a better plasma lipid profile but mild renal dysfunction as compared to non-TDF based regimens. Patients with high BMI, high baseline TG, high baseline TCH and low baseline eGFR should be closely monitored when using TDF-based ART.
Collapse
Affiliation(s)
- Junyang Yang
- Department of Infectious and Immune Diseases, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China; Wenzhou Medical University, Wenzhou, Zhejiang, China.
| | - Jun Chen
- Department of Infectious and Immune Diseases, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
| | - Yongjia Ji
- Department of Infectious and Immune Diseases, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
| | - Qi Tang
- Department of Infectious and Immune Diseases, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
| | - Renfang Zhang
- Department of Infectious and Immune Diseases, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
| | - Li Liu
- Department of Infectious and Immune Diseases, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
| | - Yinzhong Shen
- Department of Infectious and Immune Diseases, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
| | - Jingna Xun
- Department of Infectious and Immune Diseases, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
| | - Wei Song
- Department of Infectious and Immune Diseases, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
| | - Yang Tang
- Department of Infectious and Immune Diseases, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
| | - Zhenyan Wang
- Department of Infectious and Immune Diseases, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
| | - Tangkai Qi
- Department of Infectious and Immune Diseases, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
| | - Hongzhou Lu
- Department of Infectious and Immune Diseases, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China; Wenzhou Medical University, Wenzhou, Zhejiang, China; Department of Infectious Diseases, Huashan Hospital Affiliated to Fudan University, Shanghai, China; Department of Internal Medicine, Shanghai Medical College, Fudan University, Shanghai, China.
| |
Collapse
|